IRadimed Corp. (IRMD)

Several events impacted IRadimed Corp.'s stock price in the past six months. The FDA granted 510(k) clearance for the MRidium 3870 IV Infusion Pump System in May 2025, which is expected to drive short-term growth. The company reported record Q3 2025 revenue and EPS, exceeding expectations. Management raised full-year revenue and EPS guidance and increased dividends. There have been multiple instances of insider selling by key executives. IRadimed Corporation was named on Forbes' list of America's Most Successful Small-Cap Companies for 2024.

Specific information regarding the demand seasonality for IRadimed Corp.'s products and services was not found. However, the company's growth is expected to continue due to the demand for its innovative products, suggesting stable demand driven by the need for safe MRI procedures. The company's products are sold to hospitals and acute care facilities, which generally have consistent demand for medical equipment.

IRadimed Corp. is a medical technology company specializing in MRI-compatible medical devices, accessories, disposables, and services. It is the sole provider of a non-magnetic IV infusion pump system for safe use during MRI procedures. Major products include the MRidium MRI Compatible IV Infusion Pump Systems, the IRadimed 3880 MRI-Compatible Patient Vital Signs Monitoring System, the FMD Smart MRI Ferrous Metal Detection System, and MRI Clinical Accessories. The MRidium systems deliver anesthesia and IV fluids during MRI procedures. The 3870 model received FDA clearance in May 2025 and is ramping up for distribution in 2026. The 3880 system monitors vital signs in magnetic fields. The FMD system detects ferrous metals and reduces false alarms.

IRadimed Corp. primarily sells its products to hospitals and acute care facilities, generating most of its revenue from the United States. It also markets its products in approximately 80 countries through independent distributors, serving a global customer base across North America, Europe, Asia, and Latin America.

IRadimed Corp. has maintained a positive brand reputation due to its innovative MRI-compatible medical devices and strong financial performance. The company is recognized as a leader in developing innovative MRI-compatible medical devices and is the only known provider of a non-magnetic IV infusion pump system specifically designed for MRI procedures. It was named on Forbes' list of America's Most Successful Small-Cap Companies for 2024. Wall Street analysts have a "Moderate Buy" consensus rating for IRadimed. The FDA 510(k) clearance for its next-generation MRidium 3870 IV Infusion Pump System further solidifies its reputation.

IRadimed Corp. has 373 institutional owners and shareholders holding a total of 7,902,464 shares. Major institutional owners include BlackRock, Inc., Nine Ten Capital Management LLC, and Vanguard Group Inc. Major individual owners include Roger E. Susi, James B. Hawkins, and John F. Glenn.